Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.68 |
| ▸ | CTSK | P43235 | 4/20 | 0.68 |
| ▸ | CTSB | P07858 | 2/20 | 0.68 |
| ▸ | CTSL | P07711 | 1/20 | 0.68 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | REN | P00797 | 4/20 | 0.60 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30135036 | 1.00 | CTSS (0.68) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL6051752 | 1.00 | CTSS (0.68) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL27507036 | 1.00 | CTSS (0.68) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL20030598 | 1.00 | CTSS (0.68) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL17138015 | 1.00 | CTSS (0.68) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL6292728 | 0.95 | KLK5 (0.72) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL21473748 | 0.95 | KLK5 (0.72) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL1196457 | 0.95 | KLK5 (0.72) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL84524 | 0.95 | KLK5 (0.72) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL29586741 | 0.94 | CTSS (0.65) | CTSSCTSKCTSBCTSLKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109280075-B | Peptide amide compound, preparation method and medical application thereof | 四川海思科制药有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-11224609-B2 | Mithramycin derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-01-18 | — | — | US | disclosed |
| US-10550150-B2 | Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist | CADILA HEALTHCARE LIMITED (IN) | 2020-02-04 | — | — | US | disclosed |
| US-10550150-B2 | Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist | CADILA HEALTHCARE LIMITED (IN) | 2020-02-04 | — | — | US | disclosed |
| CN-109563133-A | POLYAMIDE COMPOUND AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20190083519-A1 | MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNITED STATES GOVERNMENT | 2019-03-21 | — | — | US | disclosed |
| CN-109280075-A | Peptide amide class compound and preparation method thereof and purposes in medicine | 四川海思科制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| US-20180282369-A1 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2018-10-04 | — | — | US | disclosed |
| EP-3294315-A2 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA OPIOID RECEPTORS (KOR) AGONIST | Cadila Healthcare Limited (IN) | 2018-03-21 | — | — | EP | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| WO-2016181408-A2 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2016-11-17 | — | — | WO | disclosed |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| CN-1196686-C | Method for storing quaternary ammonium salt | TOKUYAMA CORP (JP) | 2005-04-13 | — | — | CN | disclosed |
| CN-1372554-A | Method for preserving quaternary ammonium salts | TOKUYAMA CORP (JP) | 2002-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | TIAM1, AFF2, AFF1 | CTSS 4146/4885CTSK 4035/4885CTSB 3936/4885 |
| US-11224609-B2 | Mithramycin derivatives having increased selectivity and anti-cancer activity | TFAM, ELF3, TEAD4 | CTSS 2902/4885CTSK 3233/4885CTSB 2174/4885 |
| US-10550150-B2 | Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist | OPRK1, OPRL1, OPRD1 | CTSS 1924/4885CTSK 1506/4885CTSB 2129/4885 |
| US-20190083519-A1 | MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | TFAM, ELF3, TEAD4 | CTSS 2902/4885CTSK 3233/4885CTSB 2174/4885 |
| US-20180282369-A1 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST | OPRK1, OPRL1, OPRD1 | CTSS 2139/4885CTSK 1747/4885CTSB 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.